

---

STATUTORY INSTRUMENTS

---

**2019 No. 744**

**The Medicines for Human Use (Clinical Trials)  
(Amendment) (EU Exit) Regulations 2019**

**Amendment of regulation 35 (annual list of suspected serious adverse reactions and safety report)**

**16.**—(1) Regulation 35 is amended as follows.

(2) In paragraph (2)(b), for “EEA State” substitute “any country”.

(3) In paragraph (3)—

(a) for “an EEA State” substitute “a country”; and

(b) for sub-paragraphs (a) and (b), substitute—

“(a) the date on which the trial was authorised by a regulatory body responsible for authorising clinical trials in that country; or

(b) where the clinical trial was conducted in a country without a formal authorisation process, a date designated by the sponsor that is linked to the commencement of the first clinical trial.”.